Anti-angiogenic agents in pancreatic cancer: A review

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 5, 2011, Pages 464-469

  Assifi, Murwarid M ^a   Hines, Oscar J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Pancreatic cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CELECOXIB; CETUXIMAB; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; TALOMASTAT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; DRUG ABSORPTION; DRUG METABOLISM; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 79958119999     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011795677463     Document Type: Review

References (58)

1. American Cancer Society. 2010. http://www.cancer.org/Cancer/PancreaticCancer/OverviewGuide/pancreatic-cancer-overview-key-statistics
2. Burris, H.A. III; Moore, M.J.; Andersen, J; Green, M.R.; Rothen-berg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storni-olo, A.M.; Tarassaoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Van Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15(6), 2403-2413.
3. Moss, R.; Lee, C. Current and emerging therapies for the treatment of pancreatic cancer. Oncol. Targets and Therapy, 2010, 3, 111-127.
4. Kindler, H.L.; Friberg, G.; Singh, D.A.; Locker, G.; Nattam, S.; Kozloff, M.; Taber, D.A.; Karrison, T.; Dachman, A.; Stadler, W.M.; Vokes, E.E. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2005, 23(31), 8033-8040.
5. Moore, M.J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J.R.; Gall-inger, S.; Au, H.J.; Murawa, P.; Walde, D.; Wolff, R.A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25(15), 1960-1966.
6. Dvorak, H.F.; Brown, L.F.; Detmar, M.; Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 1995, 146(5), 1029-1039.
7. Veikkola, T.; Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol., 1999, 9(3), 211-220.
8. Duffy, J.P.; Eibl, G.; Reber, H.A.; Hines, O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol. Cancer, 2003, 2, 12.
9. Richard, D.E.; Berra, E.; Pouyssegur, J. Angiogenesis: How a tumor adapts to hypoxia. Biochem. Biophys. Res. Commun., 1999, 266(3), 718-722.
10. Paley, P.J.; Staskus, K.A.; Gebhard, K.; Mohanraj, D.; Twiggs, L.B.; Carson, L.F.; Ramakrishnan, S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 1997, 80(1), 98-106.
11. Seo, Y.; Baba, H.; Fukuda, T.; Takashima, M.; Sugimachi, K. High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer, 2000, 88(10), 2239-2245.
12. Itakura, J.; Ishiwata, T.; Friess, H.; Fujii, H.; Matsumoto, Y.; Bu-chler, M.W.; Korc, M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res., 1997, 3(8), 1309-1316.
13. Niedergethmann, M.; Hildenbrand, R.; Wostbrock, B.; Hartel, M.; Sturm, J.W.; Richter, A.; Poster, A. High expression of vascular en-dothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas, 2002, 25(2), 122-129.
14. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol., 2002, 20(21), 4368-4380.
15. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leu-covorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350(23), 2335-2342.
16. Kindler, H.L.; Niedzwiecki, D.; Hollis, D.; Sutherland, S.; Schrag, D.; Hurwitz, H.; Innocenti, F.; Mulcahy, M.F.; O'Reilly, E.; Wozniak, T.F.; Picus, J.; Bhargava, P.; Mayer, R.J.; Schilsky, R.L.; Goldberg, R.M. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol., 2010, 28(22), 3617-3622.
17. Rixe, O.; Bukowski, R.; Michaelson, M.D.; Wilding, G.; Bolte, O.; Motzer, R.J.; Bycott, P.; Liau, K.F.; Freddo, J.; Trask, P.C.; Kim, S.; Rini, B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol., 2007, 8(11), 975-984.
18. Cohen, E.E.; Rosen, L.S.; Vokes, E.E.; Kies, M.S.; Forastiere, A.A.; Worden, F.P.; Kane, M.A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D.R.; Liau, K.F.; Cohen. R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol., 2008, 26(29), 4708-4713.
19. Schiller, J.H. Efficacy and safety of axitinib (AG-013736) in patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Am. Soc. Clin. Oncol., 2007, 43, abstr 7507.
20. Spano, J.P.; Chodkiewicz, C.; Maurel, J.; Wong, R.; Wasan, H.; Barone, C.; Létourneau, R.; Bajetta, E.; Pithavala, Y.; Bycott, P.; Trask, P.; Liau, K.; Ricart, A.D.; Kim, S.; Rixe, O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomized phase II study. Lancet, 2008, 371(9630), 2101-2108.
21. Wieduwilt, M.J.; Moasser, M.M. The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol. Life Sci., 2008, 65(10), 1566-1584.
22. Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Berger, H.G.; Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreastic cancer is associated with enhanced tumor aggressiveness. Anticancer Res., 1993, 13(3), 565-569.
23. Sato, J.D.; Kawamoto, T.; Le, A.D.; Mendelson, J.; Polikoff, J.; Sato, G.H.; Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med., 1983, 1(5), 511-529.
24. Bruns, C.J.; Harbison, M.T.; Davis, D.W.; Portera, C.A.; Tsan, R.; McConkey, D.J.; Evans, D.B.; Abbruzzese, J.L.;I Hicklin, D.J.; Radinsky, R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthoteopically nude mice by antiangiogenic mechanisms. Clin. Cancer Res., 2000, 6(5), 1936-1948.
25. Xiong, H.Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R.A.; Deutsch, J.; Needle, M.; Abbruzzese, J.L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol., 2004, 22(13), 2610-2616.
26. Philip, P.H.; Benedetti, J.; Corless, C.L.; Wong, R.; O'Reilly, E.M.; Flynn, P.J.; et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial SO205. J. Clin. Oncol., 2010, 28(22), 3605-3610.
27. Tarceva prescribing information, 2004. http://www.tarceva.com
28. Ng, S.S.; Tsao, M.S.; Nicklee, T.; Headley, D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther., 2002, 1(10)777-783.
29. Dragovich, T.; Huberman, M.; Von Hoff, D.D.; Rowinsky, E.K.; Nadler, P.; Wood, D.; Hamilton, M.; Hage, G.; Wolf, J.; Patnaik, A. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Cher-mother. Pharmacol., 2007, 60(2), 295-303.
30. OSI Pharmaceuticals, Inc. Tarceva Prescribing Information. http://www.gene.com
31. Van Cutsem, E.; Vervenne, W.L.; Bennouna, J.; Humblet, Y.; Gill, S.; Van Laethem, J.L.; Verslype, C.; Scheithauer, W.; Shang, A.; Cosaert, J.; Moore, M.J. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol., 2009, 27(13), 2231-2237.
32. Perez-Soler, R.; Saltz, L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J. Clin. Oncol., 2005, 23(22), 5235-5246.
33. Zhou, X.C.; Tang, C.W.; Liu, C.L.; Wang, C.H. Effects of re-fecoxib on angiogenesis of pancreatic cancer xenograft in nude mice. Ai Zheng, 2004, 23(4), 376-380.
34. Xiong, H.Q. Molecular targeting therapy for pancreatic cancer. Cancer Chmother. Pharmacol., 2004, 54(Suppl 1), S69-S77.
35. Tucker, O.N.; Dannenberg, A.J.; Yang, E.K.; Zhang, F.; Teng, L.; Daly, J.M.; Soslow, R.A.; Masferrer, J.L.; Woerner, B.M.; Koki, A.T.; Fahey, T.J. 3rd. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res., 1999, 59(5), 987-990.
36. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 2000, 342(26), 1946-1952.
37. Dragovich, T.; Burris, H.; Loehrer, P.; Von Hoff, D.D.; Chow, S.; Stratton, S.; Green, S.; Obregon, Y.; Alvarez, I.; Gordon, M. Gemcitabine Plus Celecoxib in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma: Results of a Phase II Trial. Am. J. Clin. Oncol., 2008, 31(2), 157-162.
38. Foda, H.D.; Zucker, S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Disc. Today, 2001, 6(9), 478-482.
39. John, A.; Tuszynski, G.P. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res., 2001, 7(1), 14-23.
40. Bramhall, S.R.; Schulz, J.; Nemunaitis, J.; Brown, P.D.; Baillet, M.; Buckels, J.A. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer, 2002, 87(2), 161-167.
41. Moore, M.J.; Hamm, J.; Dancey, J.; Eisenberg, P.D.; Dagenais, M.; Fields, A.; Hagan, K.; Greenberg, B.; Colwell, B.; Zee, B.; Tu, D.; Ottaway, J.; Humphrey, R.; Seymour, L. Comparison of gemcit-abine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2003, 21(17), 3296-3302.
42. Miller, M.D.; Krangel, M.S. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol., 1992, 12(1-2), 17-46.
43. Baggiolini, M.; Walz, A.; Kunkel, S.L. Neutrophil-activating pep-tide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest., 1989, 84(4), 1045-1049.
44. Wente, M.N.; Keane, M.P.; Burkick, M.D.; Friess, H.; Buchler, M.W.; Ceyhan, G.O.; et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett., 2006, 241(2), 221-227.
45. Donahue, T.R.; Hines, O.J. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J. Surg., 2009, 33(4), 710-715.
46. Strieter, R.M.; Polverini, P.J.; Kunkel, S.L.; Arenberg, D.A.; Burdick, M.D.; Kasper, J.; Dzuiba, J.; Van Damme, J.; Walz, A.; Marriott, D.; The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem., 1995, 270(45), 27348-27357.
47. Arenberg, D.A.; Keane, M.P.; DiGiovine, B.; Kunkel, S.L.; Morris, S.B.; Xue, Y.Y.; et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest., 1998, 102(3), 465-472.
48. Addison, C.L.; Arenberg, D.A.; Morris, S.B.; Xue, Y.Y.; Burdick, M.D.; Mulligan, M.S.; et al. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum. Gene Ther., 2000, 11(2), 247-261.
49. Addison, C.L.; Daniel, T.O.; Burdick, M.D.; Liu, H.; Ehlert, J.E.; Xue, Y.Y.; et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. J. Immunol., 2000, 165(9), 5269-5277.
50. Li, A.; King, J.; Moro, A.; Sugi, M.D.; Dawson, D.W.; Kaplan, J.; et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol., 2011, 178(3), 1340-1349.
51. Berlin, J.D.; Catalano, P.; Thamas, J.P.; Kugler, J.W.; Haller, D.G.; Benson, A.B. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol., 2002, 20(15), 3270-3275.
52. Rocha Lima, C.M.; Green, M.R.; Rotche, R.; Miller, Jr. W.H.; Jeffrey, G.M.; Cisar, L.A.; et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol., 2004, 22(18), 3776-3783.
53. Reiss, H.; Helm, A.; Niedergethmann, M.; Schmidt-Wolf, I.; Moik, M.; Hammer, C. A randomized, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine in patients with advanced pancreatic cancer. ASCO Annual Meeting. J. Clin. Oncol., 2005, 23 Suppl 16. Abstract LBA 4009.
54. Louvet, C.; Labianca, R.; Hammel, P.; Lledo, G.; Zampino, M.G.; Andre, T.; et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol., 2005, 23(15), 3509-3516.
55. Oettle, H.; Richards, D.; Ramanathan, R.K.; van Laethem, J.L.; Peeters, M.; Fuchs, M.; et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol., 2005, 16(10), 1639-1645.
56. Heinemann, V.; Quietzsch, D.; Gieseler, F.; Gonnermann, M.; Schonekas, H.; Rost, A.; et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol., 2006, 24(24), 3946-3952.
57. Stathopoulos, G.P.; Syrigos, K.; Aravantinos, G.; Polyzos, A.; Papakotoulas, P.; Fountzilas, G.; et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br. J. Cancer, 2006, 95(5), 587-592.
58. Poplin, E.; Feng, Y.; Berlin, J.; Rothenberg, M.L.; Hochster, H.; Mitchell, E.; et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-min infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol., 2009, 27(23), 3778-3785.